Generate:Biomedicines announced the start of two large Phase 3 trials for its lead TSLP (thymic stromal lymphopoietin) antibody, marking a key clinical inflection for the AI‑driven biotech. The company said the studies will evaluate the candidate’s efficacy in indications aligned with TSLP biology and follow promising earlier‑stage data. Generate highlights the milestone as evidence that algorithm‑designed therapeutics can progress to registrational testing. The company, based in Somerville, MA, has positioned machine‑assisted protein design and discovery at the core of its pipeline; moving an asset into Phase 3 signals maturation from discovery to late‑stage clinical development. Regulatory interactions, enrollment scale and comparator choices will determine timelines and commercial prospects. The programs also test investor hypotheses about whether AI‑first discovery platforms can deliver de‑risked clinical candidates at scale.